Onchocerca volvulus microfilariae in the anterior chambers of the eye and ocular adverse events after a single dose of 8 mg moxidectin or 150 µg/kg ivermectin: results of a randomized double-blind Phase 3 trial in the Democratic Republic of the Congo, Ghana and Liberia

Table 8 Participants with ocular Mazzotti reactions starting within 1 Month of treatment among participants with both eyes evaluated by treatment

	Moxidectin	N = 973¹	Ivermectin	N = 490¹
Mazzotti sign/ symptom	n	%	n	%
Eye pruritus	45	4.62	12	2.45
Conjunctivitis	41	4.21	15	3.06
Eye pain	29	2.98	8	1.63
Eyelid oedema	20	2.06	5	1.02
Ocular discomfort²	9	0.92	5	1.02
Tearing/watery eyes	7	0.72	7	1.43
Blurred vision	3	0.31	3	0.61
Photophobia	2	0.21	1	0.20
Peripheral sensory phenomena³	1	0.10	2	0.41
Visual acuity⁴	1	0.10		0
Total number of participants with at least 1 ocular Mazzotti reaction	121	12.4	50	10.2
Total number of Mazzotti reactions	158		58

¹Among the nine participants who did not have both eyes evaluated at all visits they attended, one had an ocular Mazzotti reaction (pain in right eye, 26 days after ivermectin treatment)
²Verbatims for ‘Ocular discomfort’ included in the moxidectin arm: ‘ocular discomfort’ (n = 5), ‘foreign body sensation in eyes’ (n = 3) and ‘sandy sensation of eyes’ (n = 1) and in the ivermectin arm ‘ocular discomfort’ (n = 2), ‘foreign body sensation in eyes’ (n = 2) and ‘cumbersome upper eyelids’ (n = 1)
³Verbatims for ‘peripheral sensory phenomena’ included ‘heavy sensation of the eyelids’ (moxidectin, duration 1 day), ‘sandy sensation in eyes’ (ivermectin, duration 7 days) and ‘burning sensation in the eyes’ (ivermectin, duration 132 days)
⁴Verbatim: ‘reduced vision’ (moxidectin, duration 1 day)

ISSN: 1756-3305